Immunology

The Immunology Department at St James’s hospital  runs a number of both investigator-led and industry centered drug trials in Immunology.

Current Trials & Studies
Study NameStudy TitleStudy TypeSponsorSponsor Type
CHAPTER 4 C307A Long-term, Open-label Study to Evaluate the Safety and Efficacy of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with Hereditary AngioedemaClinical TrialPharvarisCommercial : Industry
Chapter 3 - C303A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant Extended-release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with Hereditary AngioedemaClinical TrialPharvarisCommercial : Industry
Pharvaris/Rapide-3 A Phase 3, Randomized, Double-blind, Placebo-controlled, Cross-over Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adults with Hereditary AngioedemaClinical TrialPharvaris Commercial : Industry
PharvarisA Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency (Type I or Clinical trial (2021-000227-13)Pharvaris Commercial: Industry
STOP CSUA STOP CSUA: phySical acTivity, mOod and sleeP in Chronic Spontaneous Urticaria and AngioedemaObservational-non invasive University Non-commercial: Academic
HyQviaNon-interventional Post-Authorization Safety Study on the Long-Term Safety of HyQvia in Subjects treated with HyQviaObservational-non invasive (NCT01034969)BaxaltaCommercial: Industry
IOS registryIcatibant Outcome Survey (IOS) registry protocolObservational-non invasive (NCT01034969)ShireCommercial: Industry
REPLINISHA randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with polymyalgia rheumatica (PMR)Clinical trialNovartisCommercial: Industry
ESIDDatabase of Patients with Immunodeficiency in Ireland: in conjunction with European Society for Immunodeficiency (ESID)Observational-non invasiveNational (Government agency)Non-commercial: Hospital
ESSENCEThe effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitisClinical trialNovo NordiskCommercial: Industry
Past Trials & Studies
Study NameStudy TitleStudy TypeSponsorSponsor Type
HAE Survey Burden of hereditary angioedema (HAE) and impact on quality of life: A multi-national survey of patients and caregiversObservational-non invasive Takeda Commercial: Industry
CDZ OLEAn open-label, non-randomized extension study to evaluate the long term safety, tolerability, efficacy and pharmacokinetics of CDZ173 in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency)Clinical Trial (NCT02859727)(2016-000468-41)NovartisCommercial: Industry
CDZAn open-label, non-randomized, within-patient dose-finding study followed by a randomized, subject, investigator and sponsor-blinded placebo controlled study to assess the efficacy and safety of CDZ173 in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency)Clinical Trial (NCT02435173) (2014-003876-22)NovartisCommercial: Industry
POETYK SLE - 1A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)Clinical trial (NCT05617677)SyneosCommercial: Industry